Abstract
Purpose. The focus of this paper is to demonstrate that pegylation of a therapeutic protein, recombinant human granulocyte colony stimulating factor (PEG-G-CSF), results in an increase in stability and in retention of in vivo bioactivity when administered by the intraduodenal route and may, therefore, be a suitable form of the protein for inclusion in an oral delivery formulation.
Methods. The ability of PEG-G-CSF to elicit a therapeutic response from the enteral route was investigated by two methods of intraduodenal dosing in an in vivo model to determine the optimal dosing method: by slow, constant infusion, or by a single bolus administration.
Results. Circulating levels of the proteins confirmed that PEG-G-CSF was delivered into the systemic circulation from the enteral route and that biological activity was retained. Bioavailability from the enteral route by the constant infusion method was calculated from the intravenous administration of the proteins to be between 1.8 and 3.5% while un-modified G-CSF failed to elicit a quantifiable response by this method. Bolus administration of PEG-G-CSF also resulted in biological activity although responses were short lived and significantly lower than with the pegylated formulation.
Conclusions. The possible mechanisms of enteral delivery of PEG-G-CSF are discussed. Our results indicate that oral delivery of pegylated G-CSF may be possible and in fact, preferable to using the un-modified form of the therapeutic.
Similar content being viewed by others
REFERENCES
P. L. Smith, D. A. Wall, C. H. Gochoco and G. Wilson. Routes of delivery: Case studies. (5) Oral absorption of peptides and proteins. Adv. Drug Del. Rev. 8:253–290 (1992).
S. Muranashi. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Systems. 7:1–33 (1990).
C. Delgado, G. E. Francis and D. Fisher. The uses and properties of PEG-linked proteins. Crit. Rev. in Ther. Drug Carrier Systems. 9:249–304 (1992).
M. L. Nucci, R. Shorr and A. Abuchowski. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Del. Rev. 6:133 (1991).
E. Sada, S. Katoh, K. Yamanaka and Y. Itakura. Resistance to proteolysis of antibody ligands modified with polyethylene glycol. J. Fermentation and Bioengineering. 71:137–139 (1991).
H. Tanaka, R. Satake-Ishikawa, M. Ishikawa, S. Matsuki and K. Asano. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51:3710–3714 (1991).
G. Morstyn and A. W. Burgess. Hemopoietic growth factors: A review. Cancer Res. 48:5624–5637 (1988).
S. C. Porter. Coating of Pharmaceutical Dosage Forms. In Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton, PA (1985).
Y. Ushirogawa, Y. Nakahigashi, A. Kiriyama and K. Takada. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharm. 81:133–141 (1992).
T. Y. Ma, D. Hollander, P. Krugliak and K. Katz. PEG 400, a hydrophilic molecular probe for measuring intestinal permeability. Gastroenterlogy 98:39–46 (1990).
D. Hollander, S. Koyama, V. Dadufalza, D. Q. Tran, P. Krugliak, T. Ma and K. Y. Ling. Polyethylene glycol 900 permeability of rat intestinal and colonic segments in vivo and brush border membrane vesicles in vitro. J. Lab. Clin. Med. 113:505–515 (1989).
J. R. Pappenheimer and K. Z. Reiss. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J. Membr. Biol. 100:123–136 (1987).
H. Tanaka and T. Tokiwa. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRBN8601) in the rat. Cancer Res. 50:6615–6619 (1990).
R. Satake-Ishikawa, M. Ishikawa, Y. Okada, M. Kakatini, M. Kawagishi, S. Matsuki and K. Asano. Chemical modification of recombinant human granulocyte colony-stimulating factor by polyethylene glycol increases its biological activity in vivo. Cell Structure Function. 17:157–160 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jensen-Pippo, K.E., Whitcomb, K.L., DePrince, R.B. et al. Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(ethylene glycol). Pharm Res 13, 102–107 (1996). https://doi.org/10.1023/A:1016089503186
Issue Date:
DOI: https://doi.org/10.1023/A:1016089503186